Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
MADISON, Wisc., New York, NY and ALISO VIEJO, Calif. – June 15, 2011 – Cell Line Genetics, Inc., a leader in Stem Cell Quality Assurance services and products, and Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announced today an exclusive agreement under which Cell Line Genetics will sell the Ambry StemArray™ aCGH (array Comparative Genomic Hybridization) product and related services to its current customers as well as other companies and research institutions. Both companies believe this partnership will dramatically expand the availability of the Ambry StemArray and hasten its adoption in the stem cell and regenerative medicine market globally.
"We are proud to work with Ambry Genetics, a recognized leader in genomic technologies and diagnostics services," commented Roberto Herrera, Cell Line Genetics' Chief Business Officer. "The combination of our expertise in Regenerative Medicine and Ambry Genetics' resources in both research and clinical genomics opens up a wealth of potential opportunities in product development and services. StemArray is a best-in-class aCGH design, and this is truly a win-win agreement for both our companies and, most importantly, our customers."
The Ambry Genetics StemArray is specifically designed for stem cell scientists working with human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. Under this agreement, Cell Line Genetics will market the StemArray and related services.
"We could not be more pleased about this agreement," said Ardy Arianpour, Vice President, Business Development, at Ambry Genetics. "Cell Line Genetics has the depth and breadth of experience to help us shift sales of the Ambry StemArray into high gear. The StemArray is the obvious solution for stem cell scientists requiring higher throughput technology, and those working with both hESCs and iPS cells to detect genetic gains and losses that might be missed by lower-resolution g-banded karyotyping. Our scientific expertise combined with Cell Line Genetics' strength in the karyotyping market should make for a strong synergistic partnership."
For life science research only. Not for use in diagnostic procedures.
About the Ambry StemArray™
Human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells that are cultured for an extended period of time are susceptible to chromosomal instability, a major concern for researchers. Stem cells have been traditionally characterized mainly through low-resolution karyotyping analyses, which can only identify chromosomal structural changes over 5 megabases in size. The Ambry StemArray, using array Comparative Genomic Hybridization (aCGH) technology, operates on a high-resolution full genome array with 15Kb overall medium probe spacing and increased probe coverage in over 60 stem cell-associated genes and more than 200 cancer-related genes. Custom-designed for human iPS and ES cells, the Ambry StemArray offers a reproducible, high resolution karyotyping solution with high-throughput capabilities, and is priced significantly lower than high-density oligonucleotide arrays, which are often not suitable for routine laboratory analysis.
Cell Line Genetics, Inc. is a leading provider of multi-species Quality Assurance services and products for the Stem Cell and Regenerative Medicine market. The company focuses on ensuring the genetic integrity and authentication of adult and pluripotent stem cell lines for research, preclinical and clinical studies. Headquartered in Madison, Wisconsin and with offices in New York City, CLG's clients include leading universities and research institutes, as well as biotechnology and pharmaceutical companies. For a complete list of CLG products and services please visit www.clgenetics.com
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com